ArticleMolecular microbiology2025
Targeted Deletion of the Cytopathogenic Toxin A Gene in Sneathia vaginalis.
Article in Molecular microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative genomics of Sneathia species: insights into pathogenicity and adaptation to the human niche.BMC microbiology · 2026Article
- Oral microbiome diversity, community- and taxon-level differences by oral human papillomavirus (HPV) and race/ethnicity.Infectious agents and cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Sneathia vaginalis is a common component of the vaginal microbiome and is emerging as a marker for preterm birth. It produces the cytopathogenic toxin A (CptA), which is capable of lysing human red blood cells and permeabilizing epithelial cells. However, the role of CptA and other potential virulence factors in pathogenesis has been difficult to characterize due to the lack of genetic tools for targeted deletion in S. vaginalis. The objective of this study was to create the first isogenic gene deletion mutant in S. vaginalis. We chose the cptA gene as a target for deletion because of its role in virulence. We characterized the restriction-modification profile in S. vaginalis to increase the chances that exogenous DNA would resist restriction digestion, and we identified an antibiotic resistance cassette that is functional in this species. We identified a genetic locus encoding a Dam methylase and a restriction endonuclease with DpnII-like activity in S. vaginalis strain SN35. By convention, this newly described restriction endonuclease would be named SvaSI for S. vaginalis SN35. Using plasmid DNA purified from a Dam+ E. coli strain to evade SvaSI restriction, we successfully replaced cptA with an erythromycin resistance cassette encoding the ermF and ermAM genes, creating the first genetically engineered deletion mutation in this species. Results revealed that CptA is necessary for the hemolytic and cytopathogenic activities of S. vaginalis. This work is a resource that lays the foundation for the development of additional genetic tools for S. vaginalis and facilitates the characterization of additional genes in this emerging pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.